Trial Profile
A Phase I Trial of Escalating Dose of RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Midostaurin (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 22 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 22 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.
- 06 Feb 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.